Cook-Deegan R, Heaney C. He did this to avoid a conflict of interest in making decisions, and to avoid being dragged into the many controversies over gene patenting and licensing and also, of course, to support the charity —in addition to supporting further CF research. If the technologies were successful, then the university would benefit in other areas, through advancing and enhancing its reputation and providing a royalty stream to support education and research. Although such a clause was not initially written into the non-exclusive license, the first licensee insisted that such a clause be added to the terms of the license agreement. The U of M gets a small payment if OneWorld Health sub-licenses to a developer, but gets no running royalties on products or services. Because the development of any therapeutic would require significant investment from a biotechnology or pharmaceutical company to bring a product through proof of clinical mechanism, clinical testing, and U.

Author information Copyright and License information Disclaimer. Which statement indicates a correct understanding of the etiology of CF? Although this model may not be successful when applied to patents that cover genetic mutations that influence rare diseases or diseases without a stable and savvy patient advocacy organization, it has held up well over the past two decades through negotiations with a variety of companies. Identification of the cystic fibrosis gene: Linkage studies with cystic fibrosis of the pancreas. When the CFF was founded in , a child born with CF was not expected to survive until elementary school; in contrast, the life expectancy today is over 37 years, and is increasing at the rate of about one year per year.

Which rationale best supports this referral?

Severity of cystic fibrosis in patients homozygous and heterozygous for delta F mutation. Ritchie argues that this clause helped maintain the long-term stury of the CFTR licensing structure by serving as a valuable tool during negotiations with companies.

Therefore, patenting made sense to the scientists, their nonprofit institutions, and disease advocacy groups. They are perhaps most important for how they managed to keep out of the way—how the licensing strategy retained freedom to do research and creative use of the patent incentive to promote promising therapeutics while also permitting many approaches to screening and diagnosis by many providers and generating modest revenue for further research and education.


This lower diagnostic testing price has had the additional benefit of enabling many states to implement CF screening into newborn screening programs.

Pediatric Cystic Fibrosis Case Study

This mucus makes it difficult for patients to clear lung infections, which are the leading cause of death in CF. In order to learn more about how this successful licensing model came about, we expanded the previous case study by interviewing key players in the process:.

These features led to the development of a licensing model that has not only allowed the patent holders to avoid the controversy that has plagued other gene patents, but has also allowed research, development of new therapeutics, and wide-spread dissemination of genetic testing for cystic fibrosis.

Which statement by the mother supports the diagnosis of CF? Managing Innovation for a Better World. Three or four licenses had cysic because research on gene therapy failed to progress to market.

NumberDecember Instead, because the U of M gave the CFF the right to sub-license, companies only need to deal with the CFF, thereby reducing the amount of time they have to deal with obtaining a license from the U of M and expediting their research by a few months.

As genetic mapping technologies improved, especially in the s with the discovery and implementation of restriction fragment length polymorphisms, the pace of discovery rapidly increased. The search for the genetic underpinning of CF began in the s with unsuccessful attempts to identify linkage with known blood groups 16 Impact of gene patents and licensing practices on access to genetic testing for Alzheimer disease. Csae documentation further supports the diagnosis of CF?

While the U of M administers all U.

Cystic Fibrosis Patents: A Case Study of Successful Licensing

The clause was incorporated into every license the U of M has issued since. See other articles in PMC that cite the published article. Perform chest percussion and postural drainage 2 times a day.


hesi cystic fibrosis case study

Which nursing diagnosis has the highest priority? Although this particular licensing strategy is currently only used by the U of M with respect to the CFTR patent, Ritchie does draw from it to help draft other licensing agreements with other entities:. One further, somewhat surprising, feature of cysttic CF licensing fibroais was the humanitarian licensing of some of the same patents for developing ways to prevent or manage diarrheal diseases.

What actions should the nurse educator take to address this? In the United States, an inventor can publicize the discovery or invention before filing a patent application, but many other jurisdictions do not have such a grace period and any public announcement vitiates the subsequent ability to get worldwide patent protection.

hesi cystic fibrosis case study

What are standards of care? Licensing the CFTR patents was also a tool for managing the quality of genetic testing on at least one occasion 2. Make arrangements to meet with Paula privately at the first opportunity. It distinguished the CF licensing process from patenting and licensing of Canavan Disease 4 and BRCA 5 patents for genetic testing, where patent-related controversy dogged the history of genetic diagnostics. Cystlc is concerned that his wife is going to leave him.

No notification letter was sent, and apparently the laboratory quietly withdrew from the market, or at least stopped advertising its CF testing gesi so publicly.

Pediatric Cystic Fibrosis Case Study

Several firms also developed different multi-allele or full gene sequence-based tests or test kits that became available commercially. Not much was known about whether a potential protein-based therapeutic could be developed, since the function of the CFTR gene was not yet known, other than hints it was an ion channel for chloride.

How about receiving a customized one?